Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Azacitidine in MDS
NCT00384956Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Washington University School of Medicine. Primary endpoint: Rate of Complete Remission (CR) and Partial Remission (PR). Started Aug 2006; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00384956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384956.